S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
New CBOE “special perk” helps traders target income every weekend (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

VBI Vaccines (VBIV) Earnings Date, Estimates & Call Transcripts

$0.71
+0.02 (+2.90%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.69
$0.72
50-Day Range
$0.50
$0.71
52-Week Range
$0.45
$21.00
Volume
70,369 shs
Average Volume
156,659 shs
Market Capitalization
$16.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Earnings Summary

Upcoming
Earnings Date
Mar. 11Estimated
Actual EPS
(Nov. 14)
-$0.38 Missed By -$0.24
Consensus EPS
(Nov. 14)
-$0.14
Skip Charts & View Estimated and Actual Earnings Data

VBIV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VBIV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

VBI Vaccines Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.08)($0.07)($0.08)
Q2 20232($0.07)($0.07)($0.07)
Q3 20232($0.07)($0.07)($0.07)
Q4 20232($0.07)($0.06)($0.07)
FY 20238($0.29)($0.27)($0.28)

VBIV Earnings Date and Information

VBI Vaccines last posted its earnings results on November 14th, 2023. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.24. The company earned $6.62 million during the quarter, compared to analysts' expectations of $13.25 million. VBI Vaccines has generated ($11.68) earnings per share over the last year (($11.68) diluted earnings per share). Earnings for VBI Vaccines are expected to grow in the coming year, from ($2.16) to ($0.82) per share. VBI Vaccines has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 11th, 2024 based off prior year's report dates.

VBI Vaccines Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/11/2024
Estimated)
------- 
11/14/2023Q3 2023($0.14)($0.38)($0.24)$0.25$13.25 million$6.62 million
8/14/2023Q2 2023($2.16)($2.17)($0.01)$0.71$1.46 million$0.72 million
5/15/2023Q1 2023($2.27)($2.43)($0.16)($1.64)$0.82 million$0.49 million
3/13/2023Q4 2022($1.40)($1.60)($0.20)($0.08)$1.98 million$0.29 million
11/10/2022Q3 2022($1.60)($1.80)($0.20)($0.08)$1.29 million$0.32 million
8/8/2022Q2 2022($1.40)($3.60)($2.20)($0.18)$0.70 million$0.35 million
5/9/2022Q1 2022($1.60)($1.60)-($0.08)$0.13 million$0.13 million
3/7/2022Q4 2021($1.40)($1.40)-($0.07)$0.14 million$0.08 million
11/8/2021Q3 2021($1.40)($1.20)+$0.20($0.06)$0.26 million$0.11 million
8/1/2021Q2 2021($1.40)($1.40)-($0.07)$0.55 million$0.14 million
5/10/2021Q1 2021($1.20)($1.40)($0.20)($0.07)$0.51 million$0.30 million
3/1/2021Q4 2020($1.20)($1.20)-($0.06)$0.44 million$0.16 million












VBI Vaccines Earnings - Frequently Asked Questions

When is VBI Vaccines's earnings date?

VBI Vaccines has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 11th, 2024 based off last year's report dates. Learn more on VBIV's earnings history.

Did VBI Vaccines beat their earnings estimates last quarter?

In the previous quarter, VBI Vaccines (NASDAQ:VBIV) missed the analysts' consensus estimate of ($0.14) by $0.24 with a reported earnings per share (EPS) of ($0.38). Learn more on analysts' earnings estimate vs. VBIV's actual earnings.

How much revenue does VBI Vaccines generate each year?

VBI Vaccines (NASDAQ:VBIV) has a recorded annual revenue of $8.12 million.

How much profit does VBI Vaccines generate each year?

VBI Vaccines (NASDAQ:VBIV) has a recorded net income of -$113.30 million. VBIV has generated -$11.68 earnings per share over the last four quarters.

What is VBI Vaccines's EPS forecast for next year?

VBI Vaccines's earnings are expected to grow from ($2.16) per share to ($0.82) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:VBIV) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -